Systemic Antifungal Therapy for Invasive Pulmonary Infections

Overview

Journal J Fungi (Basel)

Date 2023 Feb 25

PMID 36836260

Authors

Ronen Ben-Ami

Affiliations

Soon will be listed here.

Abstract

Antifungal therapy for pulmonary fungal diseases is in a state of flux. Amphotericin B, the time-honored standard of care for many years, has been replaced by agents demonstrating superior efficacy and safety, including extended-spectrum triazoles and liposomal amphotericin B. Voriconazole, which became the treatment of choice for most pulmonary mold diseases, has been compared with posaconazole and itraconazole, both of which have shown clinical efficacy similar to that of voriconazole, with fewer adverse events. With the worldwide expansion of azole-resistant and infections with intrinsically resistant non- molds, the need for newer antifungals with novel mechanisms of action becomes ever more pressing.

Citing Articles

Deletion of core septin gene in results in fungicidal activity of caspofungin.

Busch R, Doty C, Mills C, Latifi F, Herring L, Konjufca V bioRxiv. 2025; .

PMID: 40060473 PMC: 11888321. DOI: 10.1101/2025.02.25.640155.

Nanomedicines for Pulmonary Drug Delivery: Overcoming Barriers in the Treatment of Respiratory Infections and Lung Cancer.

Fernandez-Garcia R, Fraguas-Sanchez A Pharmaceutics. 2025; 16(12.

PMID: 39771562 PMC: 11677881. DOI: 10.3390/pharmaceutics16121584.

Poloxamer 188 stabilized poly (ε-caprolactone) microspheres of voriconazole for targeting pulmonary aspergillosis.

Singh A, Mourya A, Singh H, Bajad G, Bojja B, Arya S Ther Deliv. 2024; 16(2):155-166.

PMID: 39716773 PMC: 11849943. DOI: 10.1080/20415990.2024.2441647.

A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole.

Thompson 3rd G, Chen S, Alfouzan W, Izumikawa K, Colombo A, Maertens J Med Mycol. 2024; 62(9).

PMID: 39138063 PMC: 11382804. DOI: 10.1093/mmy/myae083.

Special Issue "Diagnosis and Treatment of Invasive Pulmonary Fungal Infections".

Lynch J, Kontoyiannis D J Fungi (Basel). 2023; 9(7).

PMID: 37504732 PMC: 10381693. DOI: 10.3390/jof9070744.

References

Thompson 3rd G, Soriano A, Cornely O, Kullberg B, Kollef M, Vazquez J . Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2022; 401(10370):49-59. DOI: 10.1016/S0140-6736(22)02324-8. View

Ullmann A, Aguado J, Arikan-Akdagli S, Denning D, Groll A, Lagrou K . Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018; 24 Suppl 1:e1-e38. DOI: 10.1016/j.cmi.2018.01.002. View

Patterson T, Thompson 3rd G, Denning D, Fishman J, Hadley S, Herbrecht R . Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4):e1-e60. PMC: 4967602. DOI: 10.1093/cid/ciw326. View

Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K . Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015; 70(11):3116-23. DOI: 10.1093/jac/dkv236. View

Gershkovich P, Wasan E, Lin M, Sivak O, Leon C, Clement J . Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother. 2009; 64(1):101-8. DOI: 10.1093/jac/dkp140. View

Bruggemann R, Alffenaar J, Blijlevens N, Billaud E, Kosterink J, Verweij P . Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009; 48(10):1441-58. DOI: 10.1086/598327. View

Alastruey-Izquierdo A, Mellado E, Pelaez T, Peman J, Zapico S, Alvarez M . Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob Agents Chemother. 2013; 57(7):3380-7. PMC: 3697314. DOI: 10.1128/AAC.00383-13. View

Dolton M, Ray J, Marriott D, McLachlan A . Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012; 56(6):2806-13. PMC: 3370770. DOI: 10.1128/AAC.05900-11. View

Arendrup M, Friberg N, Mares M, Kahlmeter G, Meletiadis J, Guinea J . How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Clin Microbiol Infect. 2020; 26(11):1464-1472. DOI: 10.1016/j.cmi.2020.06.007. View

10.

Branch R . Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med. 1988; 148(11):2389-94. View

11.

Espinel-Ingroff A . In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol. 2004; 20(4):121-36. View

12.

De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N . The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses. 1988; 31(9):476-85. DOI: 10.1111/j.1439-0507.1988.tb03653.x. View

13.

Skiada A, Pagano L, Groll A, Zimmerli S, DuPont B, Lagrou K . Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011; 17(12):1859-67. DOI: 10.1111/j.1469-0691.2010.03456.x. View

14.

Arendrup M, Jensen R, Meletiadis J . In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order. Antimicrob Agents Chemother. 2015; 59(12):7735-42. PMC: 4649229. DOI: 10.1128/AAC.01919-15. View

15.

Agarwal R, Vishwanath G, Aggarwal A, Garg M, Gupta D, Chakrabarti A . Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses. 2013; 56(5):559-70. DOI: 10.1111/myc.12075. View

16.

Kraft W, Chang P, van Iersel M, Waskin H, Krishna G, Kersemaekers W . Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014; 58(7):4020-5. PMC: 4068532. DOI: 10.1128/AAC.02448-13. View

17.

Lepak A, Andes D . Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med. 2014; 5(5):a019653. PMC: 4448584. DOI: 10.1101/cshperspect.a019653. View

18.

Krishna G, Ma L, Martinho M, Preston R, OMara E . A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012; 67(11):2725-30. PMC: 3468079. DOI: 10.1093/jac/dks268. View

19.

Zonios D, Gea-Banacloche J, Childs R, Bennett J . Hallucinations during voriconazole therapy. Clin Infect Dis. 2008; 47(1):e7-e10. PMC: 2727751. DOI: 10.1086/588844. View

20.

Ullmann A, Akova M, Herbrecht R, Viscoli C, Arendrup M, Arikan-Akdagli S . ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012; 18 Suppl 7:53-67. DOI: 10.1111/1469-0691.12041. View